Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070665 | 0.88 | MMP1 (0.34) | MEN1GAAKMT2ACA2MAPK1 | |
| SCHEMBL9995723 | 0.86 | MMP3 (0.39) | MEN1GAAKMT2ATDP1 | |
| SCHEMBL10830748 | 0.83 | CHRM1 (0.44) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL23855055 | 0.82 | TGFBR1 (0.36) | TGFBR1 | |
| SCHEMBL394954 | 0.82 | TGFBR1 (0.36) | TGFBR1 | |
| SCHEMBL657408 | 0.81 | GABRR1 (0.45) | — | |
| SCHEMBL559017 | 0.81 | GRN (0.31) | MEN1GAAKMT2A | |
| SCHEMBL4067055 | 0.81 | MEN1 (0.30) | MEN1GAAKMT2A | |
| SCHEMBL3641426 | 0.81 | ALDH1A1 (0.31) | MEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL1026854 | 0.79 | GABRR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008062-B1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-04-05 | — | — | EP | disclosed |
| US-9586958-B2 | Prodrug derivatives of substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20160207915-A1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| EP-3008062-A2 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| WO-2014198647-A2 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| EP-2496557-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| WO-2011054841-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-7928225-B2 | Oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2011-04-19 | — | — | US | disclosed |
| EP-1948185-A2 | INHIBITORS OF AKT ACTIVITY | SmithKline Beecham Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1912992-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SmithKline Beecham Corporation (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1874768-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007081091-A1 | RHODANDSE DERIVARIVES, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007076423-A2 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007058852-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007017262-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006113837-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207915-A1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | TK1, PNKP, MPST | MEN1 1388/4885GAA 81/4885KMT2A 3523/4885 |
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | ELOVL3, ELOVL5, SCD5 | MEN1 3582/4885GAA 4092/4885KMT2A 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.